Board Approves Rights Issue of ₹1,279.35 Crore at ₹750 Per Share, Ratio 2:21
The Board has approved a rights issue of 1,70,58,082 equity shares (face value ₹2) aggregating up to ₹12,79,35,61,500.
By ScoutQuest · · 2 min read
- Issue Size
- 1,70,58,082 equity shares aggregating up to ₹12,79,35,61,500
- Issue Price
- ₹750 per share, including premium of ₹748
- Entitlement Ratio
- 2 rights shares for every 21 shares held
- Record Date
- October 1, 2026
- Shares Outstanding Post-Issue
- 19,61,67,952 (from 17,91,09,870 assuming full subscription)
What was decided
The Board of Directors, at its meeting on September 25, 2026, approved the terms of a rights issue of equity shares of face value ₹ 2 each.
- Issue size: 1,70,58,082 Rights Equity Shares aggregating up to ₹12,79,35,61,500, assuming full subscription and subject to finalisation of Basis of Allotment.
- Issue price: ₹ 750 per share, which includes a premium of ₹ 748 per share.
- Entitlement ratio: 2 Rights Equity Shares for every 21 fully paid-up equity shares held on the record date.
- Record date: October 1, 2026.
Timeline
- Issue opens: Monday, 12th October, 2026.
- Issue closes: Thursday, 22nd October, 2026.
- On-market renunciation period: Monday, 12th October, 2026 to Friday, 16th October, 2026.
Effect on share count
- Equity shares before the rights issue: 17,91,09,870.
- Equity shares after the rights issue: 19,61,67,952, assuming full subscription.
Shareholders who do not apply will see their proportionate holding reduced, since new shares are issued. Those who do not wish to subscribe can sell their rights entitlements during the on-market renunciation window.
Fractional and small holdings
If a holding is less than 21 shares or not a multiple of 21, the fractional entitlement is ignored. Such shareholders get preferential consideration for allotment of one additional Rights Equity Share if they apply for additional shares, subject to availability. Holders of fewer than 21 shares get 'zero' rights entitlement, may apply for additional shares with preference for one share, but cannot renounce in favour of third parties.
Rights entitlements on shares under dispute, court proceedings, transmission, or held in a demat suspense account will be kept in abeyance until the matter is resolved.
Other business
The Board also approved an amendment to the Code of Conduct to regulate, monitor and report trading by designated persons, which will be available on the Company's website.
BSE and NSE had given in-principle approval for the proposed rights issue by letters each dated September 21, 2026. Remaining terms will be set out in the Letter of Offer to be shared.
How investors may read it
A rights issue raises fresh equity capital from existing shareholders. Perception usually depends on the intended use of funds and the pricing relative to the market. Shareholders should note the record date and the application window if they wish to participate.
Also from Natco Pharma
Allotment of ~1.71 crore equity shares at ₹750 each under rights issue
23 Oct 2026
Rights Issue period closes today; issue of up to Rs.12,794 millions approved at Rs.750 per share
22 Oct 2026
Carboplatin Injection, generic of Paraplatin, launched in the U.S. market
19 Oct 2026
More numbers
- Rights issue size₹12,79,35,61,500/-
- Number of rights equity shares1,70,58,082
- Rights issue price per share₹ 750/-
- Premium per share₹ 748/-
- Face value per share₹ 2
- Rights shares offered per 21 held2
- Existing shares required for entitlement21
- Shares outstanding prior to rights issue17,91,09,870
- Shares outstanding post rights issue19,61,67,952
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.